- Home
- LTM vs EXEL Comparison
LTM vs EXEL Comparison
Compare LTM & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTM
- EXEL
- Stock Information
- Founded
- LTM 1929
- EXEL 1994
- Country
- LTM Chile
- EXEL United States
- Employees
- LTM N/A
- EXEL N/A
- Industry
- LTM
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LTM
- EXEL Health Care
- Exchange
- LTM NYSE
- EXEL Nasdaq
- Market Cap
- LTM 8.9B
- EXEL 9.8B
- IPO Year
- LTM N/A
- EXEL 2000
- Fundamental
- Price
- LTM $33.37
- EXEL $36.17
- Analyst Decision
- LTM Strong Buy
- EXEL Buy
- Analyst Count
- LTM 3
- EXEL 18
- Target Price
- LTM $38.00
- EXEL $37.59
- AVG Volume (30 Days)
- LTM 585.0K
- EXEL 2.2M
- Earning Date
- LTM 01-01-0001
- EXEL 05-13-2025
- Dividend Yield
- LTM 3.27%
- EXEL N/A
- EPS Growth
- LTM 49.49
- EXEL 170.77
- EPS
- LTM 0.00
- EXEL 1.76
- Revenue
- LTM $12,914,322,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- LTM $8.51
- EXEL $5.78
- Revenue Next Year
- LTM $4.63
- EXEL $10.94
- P/E Ratio
- LTM $9.41
- EXEL $20.64
- Revenue Growth
- LTM 6.41
- EXEL 18.50
- 52 Week Low
- LTM $21.83
- EXEL $20.14
- 52 Week High
- LTM $33.50
- EXEL $40.26
- Technical
- Relative Strength Index (RSI)
- LTM N/A
- EXEL 43.89
- Support Level
- LTM N/A
- EXEL $34.90
- Resistance Level
- LTM N/A
- EXEL $40.26
- Average True Range (ATR)
- LTM 0.00
- EXEL 1.21
- MACD
- LTM 0.00
- EXEL -0.19
- Stochastic Oscillator
- LTM 0.00
- EXEL 23.69
About LTM LATAM AIRLINES GROUP SA SPON ADS EACH REP 2000 SHS
LATAM Airlines Group SA operates as a passenger airline group. The company and its affiliates provide domestic services in Brazil, Chile, Peru, Colombia, and Ecuador, as well as regional flights and long-haul operations. LATAM group carries out cargo operations using both belly space on passenger flights and dedicated freighter aircraft. In addition, it also offers complementary services, such as ground handling, courier, logistics, and maintenance. Geographically, the group generates maximum revenue from Brazil, followed by Chile, the United States of America, Peru, Europe, Colombia, Ecuador, Asia Pacific, and the rest of Latin America.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.